Supernus Pharmaceuticals Inc (NASDAQ:SUPN)’s share price reached a new 52-week high during trading on Friday . The stock traded as high as $61.25 and last traded at $59.85, with a volume of 1256411 shares traded. The stock had previously closed at $58.35.
Several equities analysts have commented on SUPN shares. BidaskClub raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, March 21st. ValuEngine upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 12th. Stifel Nicolaus upped their price target on shares of Supernus Pharmaceuticals from $50.00 to $60.00 and gave the company a “buy” rating in a report on Friday, May 25th. Finally, Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Saturday, May 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Supernus Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $52.55.
The company has a current ratio of 4.90, a quick ratio of 4.74 and a debt-to-equity ratio of 0.90. The firm has a market cap of $3.02 billion, a PE ratio of 47.50 and a beta of 1.10.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.16. Supernus Pharmaceuticals had a net margin of 21.89% and a return on equity of 30.18%. The company had revenue of $90.43 million during the quarter, compared to analysts’ expectations of $85.26 million. During the same period in the prior year, the company earned $0.19 earnings per share. The business’s quarterly revenue was up 57.1% compared to the same quarter last year. equities analysts forecast that Supernus Pharmaceuticals Inc will post 1.9 EPS for the current fiscal year.
In related news, VP Padmanabh P. Bhatt sold 7,795 shares of the stock in a transaction dated Friday, June 29th. The shares were sold at an average price of $59.92, for a total value of $467,076.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 7,205 shares of the stock in a transaction dated Thursday, June 21st. The shares were sold at an average price of $60.00, for a total transaction of $432,300.00. Following the completion of the sale, the vice president now owns 14,705 shares of the company’s stock, valued at approximately $882,300. The disclosure for this sale can be found here. In the last quarter, insiders sold 227,850 shares of company stock valued at $11,759,301. 6.20% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Avalon Advisors LLC lifted its stake in shares of Supernus Pharmaceuticals by 10.4% in the first quarter. Avalon Advisors LLC now owns 37,289 shares of the specialty pharmaceutical company’s stock valued at $1,708,000 after buying an additional 3,525 shares during the period. Mount Yale Investment Advisors LLC bought a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at about $238,000. Diversified Trust Co bought a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at about $211,000. Allianz Asset Management GmbH lifted its stake in shares of Supernus Pharmaceuticals by 60.3% in the first quarter. Allianz Asset Management GmbH now owns 278,701 shares of the specialty pharmaceutical company’s stock valued at $12,765,000 after buying an additional 104,829 shares during the period. Finally, Summit Trail Advisors LLC lifted its stake in shares of Supernus Pharmaceuticals by 11.1% in the first quarter. Summit Trail Advisors LLC now owns 42,353 shares of the specialty pharmaceutical company’s stock valued at $1,617,000 after buying an additional 4,245 shares during the period. Institutional investors and hedge funds own 97.36% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.